A real-world study compares tofacitinib and belimumab for maintenance therapy in systemic lupus erythematosus. The findings contribute to understanding treatment options for this complex autoimmune disease.
tofacitinib versus belimumab in maintenance therapy of systemic lupus erythematosus a real world cstar cohort study
Original title: “Tofacitinib versus belimumab in maintenance therapy of systemic lupus erythematosus: A real-world CSTAR cohort study.”